Actavis Settles Patent Dispute with Valeant Pharmaceuticals

Actavis Inc (NYSE:ACT) and Valeant Pharmaceuticals International Inc (TSX:VRX, NYSE:VRX) announced that the former has reached an agreement with Valeant Pharmaceuticals’ subsidiary, Medicis Pharmaceutical Corporation, to resolve an outstanding litigation related to Actavis’ ANDA for Clindamycin and Tretinoin Gel (generic version of Ziana^®) and ANDA for Imiquimod Cream (generic version of Zyclara^®).

As quoted in the press release:

Under the terms of the agreement related to Actavis’ generic version of Ziana^®, Actavis may launch its generic product in July 2016, or earlier under certain circumstances.

Under the terms of the agreement related to Actavis’ generic version of Zyclara^®, Actavis may launch its generic product on Jan. 1, 2019, or earlier under certain circumstances.

Click here to read the full Actavis Inc (NYSE:ACT) press release.